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Abortion by telemedicine in the European Union 
Tamara Hervey and Sally Sheldon  
 
 
Introduction 
This article explores one set of legal challenges raised by the interplay of two technologies. 
First, reliance on electronic media opens up the possibility of telemedicine, involving the 
provision of healthcare services in situations where the health professional and the patient 
are not in the same location. Second, safe, effective treatment protocols now exist for 
medical abortion (where a pregnancy is ended using mifepristone and misoprostol  W 
ĐŽůůĞĐƚŝǀĞůǇƌĞĨĞƌƌĞĚƚŽďĞůŽǁĂƐ ‘ĂďŽƌƚŝŽŶƉŝůůƐ ?). Combined, these two technologies open up 
the possibility of telemedical abortion services.  The clinical issues raised by this possibility 
have been widely considered [1, 2] but the regulatory issues far less so [3].  Much discussion 
of abortion law has  W quite properly  W been framed within international human rights norms. 
Here we consider something different and far less well explored. How does transnational 
trade law apply to the situation when telemedical abortion services cross national 
boundaries to enable a woman resident in a country where abortion is illegal or highly 
restricted to end an unwanted pregnancy? Can residents of these countries rely on 
transnational trade law to assert rights to receive telemedical abortion services? And can 
health professionals claim a legally protected right to treat them?    
While this discussion raises issues which resonate in other regional contexts and other 
regulatory frameworks, here we focus on how these issues might play out within the 
European Union.  The EU has a highly developed set of uniform regulations governing 
transnational trade and wide variation in domestic abortion laws. While there has been a 
gradual trend towards more permissive regulation of abortion within Europe, there 
nonetheless exists significant variation, with termination of pregnancy available on request 
within specified gestational limits in some countries (including the Netherlands, Sweden, 
and France) to others where it is permitted only in highly restricted circumstances (such as 
Northern Ireland, Malta, and Poland) [4].  Where legal local abortion services are not 
available, women will either travel to access services in other countries or end pregnancies 
outside of formal healthcare settings [5].  Many of these women will seek to have abortion 
services travel to them, through the online purchase of abortion pills.  
 
Abortion pills are readily available on the internet from a range of suppliers.  Some will 
supply pills without a medical prescription; and some of the pills thus supplied will not 
contain the indicated quantity of the active medical ingredient [6].   We do not consider 
those situations here.  Rather, we focus just on the case where authentic pills are supplied 
on prescription by an appropriately accredited doctor based in another EU country.  This 
brings legal issues of free movement of medicines and services into particularly sharp focus. 
When articulated in the language of EU law, these issues can appear very technical and far 
removed from the fundamental moral issues which underpin them.  This should not conceal 
what is at stake here: the responsible conduct of medical practice in supporting wŽŵĞŶ ?Ɛ
reproductive health; the proper role of telemedical services in allowing women to escape 
domestic criminal prohibitions that reflect religious and moral concerns for the protection of 
embryonic and fetal life (hereinafter fetal life); and the reach of EU law into sensitive moral 
matters.  
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Abortion using pills purchased online 
The safety, effectiveness and patient acceptability of abortion pills is well established [7, 8], 
including in cases when the pills are used ŝŶƚŚĞƉĂƚŝĞŶƚ ?Ɛhome [9, 10] transforming the way 
that abortion services can be offered. Here, we focus on the work of two online collectives 
of doctors and trained volunteers, who are motivated by concerns for social justice, 
reproductive health and solidarity with women facing unwanted pregnancies [2, 11, 12]. 
Following an online consultation that screens for the small number of contraindications to 
early medical abortion ĂŶĚ ĐŽŶĨŝƌŵƐ ƚŚĂƚ Ă ǁŽŵĂŶ ?Ɛ ƉƌĞŐŶĂŶĐǇ ŚĂƐ ŶŽƚ ĞǆĐĞĞĚĞĚ ŶŝŶĞ
weeks, Women on Web (WoW) and Women Help Women (WHW) each supply abortion pills 
to women in countries where abortion is legally restricted.  Each group follows a well-
established treatment protocol involving sequential administration of mifepristone followed 
by misoprostol. Clear instructions are provided both as to correct use and the symptoms 
that would require the woman to seek local aftercare, with advice and support available by 
e-mail for as long as the woman needs it.  In return, a ĚŽŶĂƚŝŽŶŽĨ ? ? ?-90 is requested from 
those who can afford it (or waived for those who cannot), with those who can afford more 
asked to contribute to supporting the provision of services for others.   
While evidence suggests that the service offered by these groups is very safe and highly 
acceptable to those who use it [13] it is subject to one important limitation: the medical 
treatment offered necessarily ends with provoking a miscarriage.  This means that women 
must seek medical treatment locally for any complications that arise. Serious infections 
requiring hospitalization are very rare and it is only in the most extreme circumstances 
(estimated at 0.03% of cases) that women require transfusion to replace excessive blood 
loss [14].  However, haemorrhage can be life-threatening if left untreated and women are 
advised to plan for it.  WoW and WHW emphasize that this makes a planned miscarriage 
considerably safer than if the same thing occurs spontaneously and that women often 
manage spontaneous miscarriages by themselves at home, with limited medical supervision. 
Research suggests that, given appropriate information, women can safely self-assess to 
confirm whether the termination is complete or whether further care is needed [15].   
It is also important to remember that the risks of a telemedical abortion be measured 
against the risks implicit in the other options available to women.  First, alongside the social, 
emotional, and financial harms that come with continuing an unwanted pregnancy to term 
are the very real clinical risks of so doing: pregnancy and childbirth carries a significantly 
higher risk of morbidity and mortality than a safely performed abortion, particularly in early 
pregnancy [16, 8].  Second, while less well documented, the need to travel to obtain an 
abortion has negative emotional, financial and health consequences [17], not least in 
delaying access to services resulting in later, higher risk procedures.  Third, where unable to 
access safe abortion services, some women will try other extreme measures to end a 
pregnancy, which are often either exceedingly dangerous, likely to be ineffective, or both.  It 
is noteworthy that the availability of abortion pills is credited with making a contribution to 
the global reduction in the number of women dying or seeking aftercare for severe 
complications following illegal abortion each year [18, 19]. 
There is thus good reason to believe that the telemedical abortion services offered by WoW 
and WHW meet the best standards of patient care and safety available, given the context in 
which they are offered.  Indeed, an Austrian court has recognised that tŽt ?Ɛ ǁŽƌŬ ŚĂƐ 
made a material contribution ƚŽǁŽŵĞŶ ?ƐŚĞĂůƚŚĂŶĚƐƵƌǀŝǀĂů ? ? ? ? ?The groups offer women 
a choice that allows them to avoid the risks of other, often unsafe, methods of abortion and 
the significant physical, emotional, social and financial burdens of continuing an unwanted 
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pregnancy.  However, highly controversially, they also enable women to avoid domestic 
legal prohibitions on abortion [21]. 
The EU law on patient choice and professional services 
 
EU law, like other trans-national trade agreements, on services, may cover situations where 
the service itself crosses a border, rather than the person who receives or provides the 
service. The provision of a medical consultation online and the prescription of abortion pills 
which are then shipped to the patient is that kind of service. The provider (health 
professional) and the receiver (patient) remain in their different states: the service crosses a 
border. In the language of trade law, non-tariff barriers to trade are, potentially, any 
domestic rules that impede the access of service providers established in one country that is 
part of a trade agreement to those in another country also bound by that trade agreement. 
[3], [22] Legal restrictions on the provision of abortion services across borders are thus non-
tariff barriers to trade. Trade agreements seek to ban or reduce the number of non-tariff 
barriers, in the name of securing free trade, which is understood to be in the interests of 
consumers and economies generally. [22] [23]  
 
EU law is a particularly dense example of this kind of trade agreement. First, it includes not 
ŽŶůǇ ƚŚĞ ƚƌĂĚĞ ĂŐƌĞĞŵĞŶƚ ŝƚƐĞůĨ  ?ƚŚĞ  ‘dƌĞĂƚǇ ŽŶ ƚŚĞ &ƵŶĐƚŝŽŶŝŶŐ ŽĨ ƚŚĞ h ? ? ďƵƚ ĂůƐŽ a 
significant web of legislation adopted by the EU institutions that applies to trade within the 
EU. Second, EU law includes mechanisms whereby individual traders (service providers and 
receivers, or in our case, health professionals and their patients) may enforce their rights 
using courts. This is relatively unusual: trade agreements usually provide only for inter-state 
dispute settlement, and/or arbitration. Third, EU law adopts a highly restrictive approach to 
rules that have the effect of trade protectionism. Any restriction of access to markets is 
treated as suspect. Impeding market access must be carefully justified, and must be a 
proportionate restriction on trade [22]. 
  
From the point of view of those seeking to provide and receive telemedical abortion 
services, EU law offers a number of important potential protections. So long as a health 
professional complies with the domestic law within the country in which she works when 
treating her patients, the starting principle is that she can use rights to trade in order to 
reach patients in other countries who wish to be treated by her. EU law gives enforceable 
rights to the health professional to offer the service, and to the patient to receive it. 
Attempts to prosecute either can also be met with a defence that the prosecution breaches 
EU law [23]. 
 
What specific EU laws might apply in this situation? While the most obvious legislation  W the 
Directive on Patients ? Rights to Cross Border Healthcare [24]  W does not cover remote 
prescribing, the e-commerce Directive [25] covers medical consultations undertaken 
through a website. And the general provision of the Treaty on the Functioning of the EU, 
Article 56, applies if the e-ĐŽŵŵĞƌĐĞŝƌĞĐƚŝǀĞĚŽĞƐŶŽƚ ?ŽƚŚƉƌŽŚŝďŝƚ ‘ƌĞƐƚƌŝĐƚŝŽŶƐ ?ŽŶĐƌŽƐƐ-
border trade in services unless those restrictions are justified by an objective public interest 
ŝŶ ƚŚĞƐƚĂƚĞ ŝŶƚĞƌǀĞŶŝŶŐ ŝŶ ƚŚĂƚ ĨƌĞĞƚƌĂĚĞ ?ĞĐĂƵƐĞĂ  ‘ƌĞƐƚƌŝĐƚŝŽŶ ? ŝƐĂŶǇƚŚŝŶŐƚŚĂƚŵĂŬĞƐ ŝƚ
harder to receive the service across borders, the important question here is whether a state 
intervening by its abortion laws is a justified trade restriction. 
 
Justified state interventions 
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No trade agreement, even one of the depth, intensity and enforceability of EU law, removes 
ĞŶƚŝƌĞůǇƐƚĂƚĞƐ ?ƐŽǀĞƌĞŝŐŶĞŶƚŝƚůĞŵĞŶƚƐŽǀĞƌ ŝŵƉŽƌƚĂŶƚŵĂƚƚĞƌƐŽĨƉƵďůŝĐƉŽůŝĐǇ or morality, 
promoting or protecting health, or securing human rights. Non-tariff barriers do not breach 
EU law if they are necessary to protect such public interests. One might thus assume that it 
would be easy for European states to argue that their abortion laws protect the broad 
purposes for which they were generally historically intended  W ƚŽƉƌŽƚĞĐƚǁŽŵĞŶ ?Ɛ health 
and/or to recognise the special moral status of the fetus  W and thus avoid any application of 
EU law to cross-border abortion by telemedicine. However, several features of EU law 
suggest that it would not be as straightforward as one might expect to assert such an 
exemption, thus leaving scope for doctors providing or patients receiving such services 
successfully to rely on EU law to defend their activities. 
 
In general, EU law respects national decisions about acceptable risks to human health and 
national articulations of morality and human rights. However, ƚŚĞh ?ƐŽƵƌƚŽĨ:ƵƐƚŝĐĞŐŝǀĞƐ
considerably less discretion to national decision-makers than does the European Court of 
Human Rights in Strasbourg. The starting point for the EU Court is that public interest 
reasons for departing from trade law are exceptions, and thus should always be narrowly 
interpreted. Further, derogations from free movement of services must mutually respect 
equivalent protections, including professional qualifications, in another EU country. Finally, 
exceptions must be part of proportionate, consistent and evidence-based national law and 
policy. 
 
This has several implications.  First, an argument that fails to treat the doctor established in 
another EU country as an equivalently competent and trusted health professional to those in 
the state where the patient is based would fail under EU law. Second, an argument that 
ƉƌŽƚĞĐƚŝŶŐ ǁŽŵĞŶ ?Ɛ ŚĞĂůƚŚ ƌĞƋƵŝƌĞƐ Ă ƌĞƐƚƌŝĐƚŝŽŶ ŽŶ ƐĞƌǀŝĐĞƐ ŽĨ ĂďŽƌƚŝŽŶ ďǇ ƚĞůĞŵĞĚŝĐŝŶĞ
would have to show that the domestic law actually works to protect health, or to prevent a 
risk of harm to women seeking abortion by telemedicine. As explained above, the treatment 
protocol used by reputable abortion service providers (such as WoW) is both safe and 
effective and any negative health consequences of telemedical use of abortion pills are 
outweighed by the health consequences of the alternative options available. There is 
ŽǀĞƌǁŚĞůŵŝŶŐĞǀŝĚĞŶĐĞ ƚŚĂƚ ƌĞƐƚƌŝĐƚŝǀĞĂďŽƌƚŝŽŶ ůĂǁƐĂƌĞǀĞƌǇŚĂƌŵĨƵů ƚŽǁŽŵĞŶ ?ƐŚĞĂůƚŚ 
and good public health arguments to believe  W in the terms of the Austrian court cited above 
 W that ƚŚĞƐĞ ŐƌŽƵƉƐ ?work makes a material contributioŶ ƚŽ ǁŽŵĞŶ ?Ɛ ŚĞĂůƚŚ ĂŶĚ ƐƵƌǀŝǀĂů 
[20].  An argument restricting cross-border abortion by telemedicine for public health 
reasons would, we think, be difficult to make convincingly. 
 
States seeking to justify their restrictive policies would thus need to relǇŽŶĂ ‘ƉƵďůŝĐƉŽůŝĐǇ ?
argument, based on a recognition of the moral status of the fetus. But these restrictions also 
have to be proportionate, taking into account equivalent protections of the relevant 
interests in the other state.  All EU countries recognise and protect the special moral status 
of the fetus, for instance, through restricting access to abortion later in pregnancy.  Further, 
while there is a wide divergence in relevant domestic laws, there is a clear trend towards 
legislation that permits greater access to services, and a majority of member states allow 
some access to abortion within early pregnancy (the period within which WoW offer 
treatment) [4].  In such a context, what might be considered outlier legal positions  W such as 
harsh criminal penalties, a failure to offer any access to services even very early in 
pregnancy, a refusal to offer abortions for fatal fetal abnormality or where there is risk to a 
ǁŽŵĂŶ ?ƐŚĞĂůƚŚand so on  W all tend to suggest the disproportionality of the policy.  
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Relying on the moral status of the fetus to restrict cross-border telemedicine services also 
goes to the question of whether protecting fetal life justifies a restriction not only on trade, 
but also on the rights of the pregnant woman to dignity and autonomy, and the freedom of 
the WoW and WHW doctors to pursue a profession. EU countries do not enjoy unrestrained 
discretion over standards of public morality. The impact of the exercise of that discretion has 
to be considered proportionate, taking account of its effects on entitlements of individual 
ǁŽŵĞŶƚŽĞǆĞƌĐŝƐĞŶŽƚŽŶůǇƚƌĂĚĞƌŝŐŚƚƐ ?ďƵƚĂůƐŽŚƵŵĂŶƌŝŐŚƚƐ ?ĂĐƌŽƐƐhďŽƌĚĞƌƐ ?tŽŵĞŶ ?Ɛ
rights such as the right to integrity of the person, freedom from inhuman and degrading 
treatment, and human dignity, are all potentially engaged.  
 
In short, we regard as far from legally certain that an EU country could successfully defend a 
policy or law that restricted the receipt of abortion services involving telemedicine by 
women in its territory, where the doctor offering the service operates lawfully from another 
EU country.   
 
Conclusions 
 
To recap: a doctor seeking to treat a patient with abortion pills is entitled, in principle, to 
rely on EU rules of free movement to protect her access to patients in other member states 
and women facing unwanted pregnancies likewise have legal rights to access the services 
thus offered. EU countries seeking to claim an exception to those rules on the basis of public 
health or on the protection of a fundamental public policy interest (here, the protection of 
fetal life) will face significant barriers. The legal burden of establishing that a derogation 
from free movement rules can be justified lies on the EU country concerned.  While again 
we have had no space to consider this further here, similar protections may be available 
under other trade agreements. 
 
It is important to emphasise again that the focus of our argument is restricted to the case of 
properly accredited doctors, acting within the law of the country from which they operate, 
to supply authentic abortion pills on prescription.  Within those limited circumstances, we 
believe that EU trade law is properly interpreted so as to offer important protections both to 
doctors and their patients. How the protections thus offered would translate into 
enforceable rights raises a further set of complexities that will depend in part on the specific 
national context and go far beyond the scope of this paper (and we have offered a more 
detailed exploration of one national context elsewhere[3]).  However, they are likely to offer 
a basis for legal challenge to any attempt by local authorities to prevent the physical 
importation of abortion pills; and to require that, insofar as possible, domestic law be 
interpreted so as to render it consistent with these international trade obligations.  This is 
not to deny that any relevant litigation would raise a range of difficult legal questions, which 
have not been fully tested in the courts.  As such, the legal pathway to challenging an 
attempt to prevent the prescription of abortion pills for a patient in one country from a 
prescribing doctor in another would inevitably be long, expensive, and contested.  
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